US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
biotech · Leber Congenital Amaurosis 10 · Sickle Cell Disease · EDIT
Editas Medicine
Editas Medicine drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2013 Founded
183 Employees
Public company Type
EDIT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2013
- Employees
- 183
- Programs
- 3
- Drugs
- 1
- Patents
- 21
Editas Medicine pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Editas Medicine drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.